Show simple item record

Authordc.contributor.authorDíaz Castro, Francisco 
Authordc.contributor.authorMonsalves Álvarez, Matías 
Authordc.contributor.authorRojo, Leonel E. 
Authordc.contributor.authorCampo, Andrea del 
Authordc.contributor.authorTroncoso, Rodrigo 
Admission datedc.date.accessioned2020-06-16T22:23:17Z
Available datedc.date.available2020-06-16T22:23:17Z
Publication datedc.date.issued2020
Cita de ítemdc.identifier.citationFront Pharmacol .(2020);11:429es_ES
Identifierdc.identifier.other10.3389/fphar.2020.00429
Identifierdc.identifier.urihttp://repositorio.uchile.cl/handle/2250/175524
Abstractdc.description.abstractA growing body of research indicates that cortisol, the glucocorticoid product of the activation of the hypothalamic-pituitary-adrenal axis, plays a role in the pathophysiology of metabolic syndrome. In this regard, chronic exposure to cortisol is associated with risk factors related to metabolic syndrome like weight gain, type 2 diabetes, hypertension, among others. Mifepristone is the only FDA-approved drug with antiglucocorticoids properties for improved the glycemic control in patients with type 2 patients secondary to endogenous Cushing's syndrome. Mifepristone also have been shown positive effects in rodents models of diabetes and patients with obesity due to antipsychotic treatment. However, the underlying molecular mechanisms are not fully understood. In this perspective, we summarized the literature regarding the beneficial effects of mifepristone in metabolic syndrome from animal studies to clinical research. Also, we propose a potential mechanism for the beneficial effects in insulin sensitivity which involved the regulation of mitochondrial function in muscle cells.es_ES
Patrocinadordc.description.sponsorshipEnlace FONDECYT-VID: EN29/18 Comisión Nacional de Investigación Cientifica y Tecnológica (CONICYT) CONICYT FONDECYT 1191078 11190756 FONDAP 15130011es_ES
Lenguagedc.language.isoenes_ES
Publisherdc.publisherFrontiers Mediaes_ES
Type of licensedc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile*
Link to Licensedc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/*
Sourcedc.sourceFrontiers in Pharmacologyes_ES
Keywordsdc.subjectRU486es_ES
Keywordsdc.subjectInsulin resistancees_ES
Keywordsdc.subjectSkeletal musclees_ES
Keywordsdc.subjectMitochondriaes_ES
Keywordsdc.subjectGlycaemiaes_ES
Títulodc.titleMifepristone for treatment of metabolic syndrome: beyond cushing’s syndromees_ES
Document typedc.typeArtículo de revistaes_ES
Catalogueruchile.catalogadorctces_ES
Indexationuchile.indexArtículo de publicación ISIes_ES


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Chile
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Chile